News
SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback